Short-term outcomes of aflibercept biosimilar SB15 in macular edema secondary to retinal vein occlusion
Abstract Purpose To evaluate the short-term outcomes of SB15, an aflibercept biosimilar approved by the U.S. Food and Drug Administration, for the treatment of macular edema secondary to retinal vein occlusion (RVO). Methods This retrospective study included 29 treatment-naïve patients diagnosed wit...
Kaydedildi:
| Asıl Yazarlar: | , , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
BMC
2026-03-01
|
| Seri Bilgileri: | BMC Ophthalmology |
| Konular: | |
| Online Erişim: | https://doi.org/10.1186/s12886-026-04683-2 |
| Etiketler: |
Etiket eklenmemiş, İlk siz ekleyin!
|